Moderna jumps on personalized mRNA Phase 3 success; raises $2.96B via 0% notes
Moderna surged on Phase 3 success for a personalized mRNA cancer vaccine with Keytruda in resected stage IIB–IV melanoma. The company also raised about $2.96B through 0% convertible notes due 2032 with capped calls.
Moderna, Inc. (NASDAQ:MRNA) surged on Phase 3 success for a personalized mRNA cancer vaccine with Keytruda in resected stage IIB—IV melanoma, fueling extreme intraday volatility and big YTD gains, even as the company raised roughly $2.96B via 0% convertible notes due 2032 with capped calls.Previous…